Cargando…

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014

Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Takashita, Emi, Meijer, Adam, Lackenby, Angie, Gubareva, Larisa, Rebelo-de-Andrade, Helena, Besselaar, Terry, Fry, Alicia, Gregory, Vicky, Leang, Sook-Kwan, Huang, Weijuan, Lo, Janice, Pereyaslov, Dmitriy, Siqueira, Marilda M., Wang, Dayan, Mak, Gannon C., Zhang, Wenqing, Daniels, Rod S., Hurt, Aeron C., Tashiro, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036627/
https://www.ncbi.nlm.nih.gov/pubmed/25721488
http://dx.doi.org/10.1016/j.antiviral.2015.02.003
_version_ 1784693557784739840
author Takashita, Emi
Meijer, Adam
Lackenby, Angie
Gubareva, Larisa
Rebelo-de-Andrade, Helena
Besselaar, Terry
Fry, Alicia
Gregory, Vicky
Leang, Sook-Kwan
Huang, Weijuan
Lo, Janice
Pereyaslov, Dmitriy
Siqueira, Marilda M.
Wang, Dayan
Mak, Gannon C.
Zhang, Wenqing
Daniels, Rod S.
Hurt, Aeron C.
Tashiro, Masato
author_facet Takashita, Emi
Meijer, Adam
Lackenby, Angie
Gubareva, Larisa
Rebelo-de-Andrade, Helena
Besselaar, Terry
Fry, Alicia
Gregory, Vicky
Leang, Sook-Kwan
Huang, Weijuan
Lo, Janice
Pereyaslov, Dmitriy
Siqueira, Marilda M.
Wang, Dayan
Mak, Gannon C.
Zhang, Wenqing
Daniels, Rod S.
Hurt, Aeron C.
Tashiro, Masato
author_sort Takashita, Emi
collection PubMed
description Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC(50)) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n = 3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n = 172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n = 32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n = 169), A(H3N2) with NA E119V (n = 1), B/Victoria-lineage with NA E117G (n = 1) and B/Yamagata-lineage with NA H273Y (n = 1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective.
format Online
Article
Text
id pubmed-9036627
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-90366272022-04-25 Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014 Takashita, Emi Meijer, Adam Lackenby, Angie Gubareva, Larisa Rebelo-de-Andrade, Helena Besselaar, Terry Fry, Alicia Gregory, Vicky Leang, Sook-Kwan Huang, Weijuan Lo, Janice Pereyaslov, Dmitriy Siqueira, Marilda M. Wang, Dayan Mak, Gannon C. Zhang, Wenqing Daniels, Rod S. Hurt, Aeron C. Tashiro, Masato Antiviral Res Article Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC(50)) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n = 3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n = 172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n = 32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n = 169), A(H3N2) with NA E119V (n = 1), B/Victoria-lineage with NA E117G (n = 1) and B/Yamagata-lineage with NA H273Y (n = 1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective. 2015-05 2015-02-23 /pmc/articles/PMC9036627/ /pubmed/25721488 http://dx.doi.org/10.1016/j.antiviral.2015.02.003 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Takashita, Emi
Meijer, Adam
Lackenby, Angie
Gubareva, Larisa
Rebelo-de-Andrade, Helena
Besselaar, Terry
Fry, Alicia
Gregory, Vicky
Leang, Sook-Kwan
Huang, Weijuan
Lo, Janice
Pereyaslov, Dmitriy
Siqueira, Marilda M.
Wang, Dayan
Mak, Gannon C.
Zhang, Wenqing
Daniels, Rod S.
Hurt, Aeron C.
Tashiro, Masato
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
title Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
title_full Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
title_fullStr Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
title_full_unstemmed Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
title_short Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
title_sort global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036627/
https://www.ncbi.nlm.nih.gov/pubmed/25721488
http://dx.doi.org/10.1016/j.antiviral.2015.02.003
work_keys_str_mv AT takashitaemi globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT meijeradam globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT lackenbyangie globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT gubarevalarisa globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT rebelodeandradehelena globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT besselaarterry globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT fryalicia globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT gregoryvicky globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT leangsookkwan globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT huangweijuan globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT lojanice globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT pereyaslovdmitriy globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT siqueiramarildam globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT wangdayan globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT makgannonc globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT zhangwenqing globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT danielsrods globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT hurtaeronc globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014
AT tashiromasato globalupdateonthesusceptibilityofhumaninfluenzavirusestoneuraminidaseinhibitors20132014